| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Thomas H. Kean Jr NJ07 | 1 | 1 | +$0 | Sold May 21, 26 |
| Kevin Hern OK01 | 1 | −$32.5K | Sold Mar 17, 26 | |
| Lisa McClain MI09 | 1 | 1 | +$0 | Sold Jun 24, 25 |
| Rob Bresnahan PA08 | 1 | 1 | +$0 | Bought May 15, 25 |
| Jefferson Shreve IN06 | 1 | −$32.5K | Sold Mar 5, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| May 21, 26 | Thomas H. Kean Jr NJ07 | Self | Sell | $1,001 - $15,000 | Jun 18, 26 (28d) | |
| Mar 17, 26 | Kevin Hern OK01 | Joint | Sell | $15,001 - $50,000 | Apr 3, 26 (17d) | |
| Jun 24, 25 | Lisa McClain MI09 | Spouse | Sell | $1,001 - $15,000 | Aug 13, 25 (50d) | |
| Jun 17, 25 | Lisa McClain MI09 | Spouse | Buy | $1,001 - $15,000 | Aug 13, 25 (57d) | |
| May 15, 25 | Rob Bresnahan PA08 | Self | Buy | $1,001 - $15,000 | Jun 9, 25 (25d) | |
| May 13, 25 | Thomas H. Kean Jr NJ07 | Self | Buy | $1,001 - $15,000 | Jun 17, 25 (35d) | |
| Apr 8, 25 | Rob Bresnahan PA08 | Self | Sell | $1,001 - $15,000 | Apr 28, 25 (20d) | |
| Mar 5, 25 | Jefferson Shreve IN06 | Self | Sell | $15,001 - $50,000 | Apr 11, 25 (37d) |
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 27, 2026 | Feld MichaelOfficer | Sale at price 183.70 per share. | 76 | $13.96K |
| Aug 25, 2026 | Feld MichaelOfficer | Sale at price 188.49 per share. | 165 | $31.10K |
| Aug 12, 2026 | Polen Thomas E JrChief Executive Officer | Sale at price 185.00 per share. | 4.2K | $768.12K |
| Aug 12, 2026 | Polen Thomas E JrChief Executive Officer | Conversion of Exercise of derivative security at price 167.25 per share. | 43.3K | $7.24M |
| Aug 10, 2026 | Goette RolandOfficer | Sale at price 180.84 per share. | 2.4K | $440.89K |
| Jul 26, 2026 | Feld MichaelOfficer | Sale at price 157.13 per share. | 75 | $11.79K |
| Jun 30, 2026 | Muhsin BilalOfficer | Stock Award(Grant) at price 0.00 per share. | 14.3K | — |
| Jun 25, 2026 | Feld MichaelOfficer | Sale at price 152.80 per share. | 75 | $11.46K |
| Jun 23, 2026 | Garrison Michael DavidOfficer | Sale at price 145.66 per share. | 1.1K | $160.23K |
| Jun 9, 2026 | Garrison Michael DavidOfficer | Sale at price 151.48 per share. | 1.1K | $166.63K |
| May 31, 2026 | Menziuso PeterOfficer | Stock Award(Grant) at price 0.00 per share. | 14.3K | — |
| May 31, 2026 | Polen Thomas E JrChief Executive Officer | Sale at price 146.35 per share. | 2.8K | $404.51K |
| May 31, 2026 | Polen Thomas E JrChief Executive Officer | Conversion of Exercise of derivative security at price 126.16 per share. | 20.2K | $2.55M |
| May 25, 2026 | Feld MichaelOfficer | Sale at price 147.35 per share. | 75 | $11.05K |
| May 6, 2026 | Roque VitorChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 1.7K | — |
| Apr 26, 2026 | Feld MichaelOfficer | Sale at price 151.94 per share. | 74 | $11.24K |
| Mar 25, 2026 | Feld MichaelOfficer | Sale at price 156.83 per share. | 75 | $11.76K |
| Mar 15, 2026 | Minnix LaneshaGeneral Counsel | Stock Award(Grant) at price 0.00 per share. | 7.5K | — |
| Mar 1, 2026 | Spikner Pamela LOfficer | Stock Award(Grant) at price 0.00 per share. | 931 | — |
| Mar 1, 2026 | Roque VitorChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 931 | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.8 | 10.3 | -10.9 | -5.2 | -1.3 | 2.9 | 9.4 | 13.6 | -4.8 | 5.5 | +23.8% | ||
| 2025 | 9.1 | -8.9 | 1.6 | -9.6 | -16.7 | -0.2 | 3.5 | 8.3 | -3.0 | -4.5 | 8.6 | 0.0 | −14.5% |
| 2024 | -2.1 | -1.4 | 5.1 | -5.2 | -1.1 | 0.8 | 3.1 | 0.6 | -0.5 | -3.1 | -5.0 | 2.2 | −7.0% |
| 2023 | -0.8 | -7.0 | 5.5 | 6.8 | -8.5 | 9.2 | 5.5 | 0.3 | -7.5 | -2.2 | -6.6 | 3.2 | −4.1% |
| 2022 | 1.1 | 6.7 | -1.9 | -4.7 | 3.5 | -3.6 | -0.9 | 3.3 | -11.7 | 5.9 | 5.7 | 2.0 | +3.6% |
| 2021 | 4.6 | -7.9 | 0.8 | 2.3 | -2.8 | 0.5 | 5.2 | -1.6 | -2.3 | -2.5 | -1.0 | 6.0 | +0.5% |
| 2020 | 1.2 | -13.6 | -3.4 | 9.9 | -2.2 | -3.1 | 17.6 | -13.7 | -4.2 | -0.7 | 1.6 | 6.5 | −8.0% |
| 2019 | 10.7 | -0.3 | 0.4 | -3.6 | -3.0 | 8.0 | 0.3 | 0.4 | -0.4 | 1.2 | 1.0 | 5.2 | +20.7% |
| 2018 | 13.5 | -8.6 | -2.4 | 7.0 | -4.4 | 8.1 | 4.5 | 4.6 | -0.3 | -11.7 | 9.7 | -10.9 | +5.3% |
| 2017 | 7.1 | 3.2 | 0.2 | 1.9 | 1.2 | 3.1 | 3.2 | -1.0 | -1.7 | 6.5 | 9.4 | -6.2 | +29.3% |
| 2016 | -5.7 | 1.4 | 3.0 | 6.2 | 3.2 | 1.9 | 3.8 | 0.7 | 1.4 | -6.6 | 0.7 | -2.1 | +7.4% |
| 2015 | -0.8 | 6.3 | -2.1 | -1.9 | -0.3 | 0.8 | 7.4 | -7.3 | -5.9 | 7.4 | 5.4 | 2.6 | +10.7% |
| 2014 | -2.1 | 6.6 | 1.6 | -3.5 | 4.1 | 0.5 | -1.7 | 0.8 | -2.9 | 13.1 | 9.0 | -0.8 | +25.9% |
| 2013 | 7.5 | 4.8 | 8.6 | -1.4 | 4.6 | 0.2 | 4.9 | -6.1 | 2.7 | 5.1 | 3.3 | 1.7 | +41.3% |
| 2012 | 4.9 | -2.8 | 1.9 | 1.0 | -6.8 | 2.2 | 1.3 | 0.4 | 3.4 | -3.7 | 1.3 | 2.0 | +4.6% |
| 2011 | -1.9 | -3.6 | -0.5 | 7.9 | 1.9 | -1.6 | -3.0 | -2.7 | -9.9 | 6.7 | -5.7 | 1.3 | −11.6% |
| 2010 | -4.4 | 3.3 | 1.1 | -3.0 | -6.6 | -5.2 | 1.7 | -0.9 | 8.7 | 1.9 | 3.2 | 8.5 | +7.2% |
| 2009 | 6.3 | -14.8 | 8.6 | -10.1 | 11.9 | 5.4 | -8.6 | 6.9 | 0.2 | -2.0 | 9.4 | 5.4 | +15.3% |
| 2008 | 3.4 | 4.6 | -5.1 | 4.1 | -5.5 | -3.7 | 4.4 | 2.9 | -8.1 | -13.5 | -8.5 | 7.6 | −18.2% |
| 2007 | 9.7 | -1.3 | 1.2 | 2.3 | -3.1 | -2.3 | 2.5 | 0.8 | 6.6 | 1.7 | -0.9 | 1.0 | +19.1% |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Buy / hold / sell counts